Boat line thousands of miles set in the anchor, the waves lift stable in the heart

Alzheimer's disease, commonly known as senile dementia, is a degenerative disease of nervous system with hidden onset and progressive development. Clinically, the main manifestations of patients are memory impairment, aphasia, apraxia, agnosia, visuospatial skills impairment, executive dysfunction, personality and behavior changes and other symptoms of generalized dementia. Its pathological features include cerebral cortex atrophy, neuron loss, age-related plaques formed by extracellular beta-amyloid deposition, and neurofibrillary tangles formed by intracellular hyperphosphorylated tau protein.

Alzheimer's disease is the most common type of dementia, accounting for about 60-80% of all dementia cases. According to the World Health Organization (WHO), there are about 50 million dementia patients worldwide, with a high proportion of them suffering from Alzheimer's disease. The number of people with dementia worldwide is expected to rise to 152 million by 2050. At present, the drugs used to treat Alzheimer's disease, such as cholinesterase inhibitors and NMDA receptor antagonists, have certain effects in improving symptoms and delaying disease progression, but they cannot cure or reverse the disease.

About 5% of Alzheimer's cases are associated with mutations in genes such as APP, PSEN1, and PSEN2. The Apolipoprotein E (APOE) gene is an important risk gene for sporadic Alzheimer's disease, and carriers of the APOEε4 allele have a significantly increased risk of developing the disease. Pathologically, normal tau protein helps maintain microtubule stability, but in the brains of Alzheimer's patients, tau protein is abnormally phosphorylated, causing it to dissociate from the microtubules and then aggregate into neurofibrillary tangles. These tangles destroy the cytoskeleton of nerve cells, affect the transport of substances within nerve cells, and eventually lead to nerve cell dysfunction and death.

In the study of microtubule motility protein, the scientists found that the metabolites of a specific group of intestinal bacteria can cross the blood-brain barrier and regulate the microtubules and microtubules of neurons in the nerve center, thereby easing the situation of microtangles of neurons. Based on this discovery, LS-LBP-04 explores the treatment of Alzheimer's disease from the perspective of structural biology and biophysics, and is expected to realize the clinical reversal of Alzheimer's disease. The pipeline innovatively applies microtubule quantum channel and quantum coherence technology to the research and development of living biological drugs.